GE HealthCare Technologies Inc. - Common Stock (GEHC)
72.24
-5.48 (-7.05%)
NASDAQ · Last Trade: Jul 30th, 3:15 PM EDT
Detailed Quote
Previous Close
77.72
Open
73.35
Bid
72.22
Ask
72.26
Day's Range
70.32 - 73.92
52 Week Range
57.65 - 94.80
Volume
9,815,094
Market Cap
32.80B
PE Ratio (TTM)
18.91
EPS (TTM)
3.8
Dividend & Yield
0.1400 (0.19%)
1 Month Average Volume
3,351,339
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Shares of healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC)
fell 6.5% in the morning session after the company reported second-quarter results that revealed significant pressure on its profit margins, overshadowing an increase in its full-year guidance. While GE HealthCare raised its full-year guidance and reported a 3% increase in revenue, investors honed in on signs of declining profitability. The company's adjusted EBIT margin, a key measure of operational profit, contracted to 14.6% from 15.3% in the prior year. This squeeze was attributed to the impact of tariffs, which productivity gains could not fully offset. The weakness was pronounced in major segments, as the Imaging division's EBIT fell by 10% and the Patient Care Solutions segment saw a significant 23% drop in EBIT. The market's negative reaction suggested these margin pressures overshadowed the company's otherwise positive outlook.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 3.5% year on year to $5.01 billion. Its non-GAAP profit of $1.06 per share was 15.5% above analysts’ consensus estimates.
Koninklijke Philips N.V. (AMS:PHIA), commonly known as Philips, is one of the most storied companies in the history of European industry. Founded in 1891 in Eindhoven, Netherlands, Philips has evolved from a modest light bulb manufacturer into a global leader in health technology and medical innovation. Its transformation
Shares of Dutch health technology company Koninklijke Philips N.V. (AMS:PHIA) surged on Tuesday, boosted by easing trade tensions and the reduction of tariffs between the European Union and major trading partners. The policy shift signals a reprieve for multinational manufacturers caught in the crossfire of protectionist economic policies
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC)
will be reporting earnings this Wednesday before the bell. Here’s what to expect.
GE HealthCare (Nasdaq: GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability.
GE HealthCare (Nasdaq: GEHC) has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device authorizations for the fourth year in a row with 100 listed authorizations to date in the U.S.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including GE HealthCare (NASDAQ:GEHC) and its peers.
The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025.
GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for its positron emission tomography (PET) imaging agent VizamylTM (flutemetamol F 18 injection) for beta-amyloid detection. The revised label, effective immediately, expands the indications for use, enables quantitative analysis of Vizamyl scans, and removes significant previous limitations such as monitoring patient response to anti-amyloid therapy.
GE HealthCare’s commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana.
At this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare’s MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response monitoring.
Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
